Compare ARQQ & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | OABI |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 294.3M |
| IPO Year | 2021 | 2021 |
| Metric | ARQQ | OABI |
|---|---|---|
| Price | $23.04 | $4.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $60.00 | $4.50 |
| AVG Volume (30 Days) | 331.6K | ★ 1.4M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | $381.13 | $52.42 |
| Revenue Next Year | $212.00 | $64.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.52 | $1.32 |
| 52 Week High | $62.00 | $5.43 |
| Indicator | ARQQ | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 60.73 |
| Support Level | $21.90 | $1.90 |
| Resistance Level | $24.10 | $5.43 |
| Average True Range (ATR) | 1.63 | 0.25 |
| MACD | 0.33 | -0.02 |
| Stochastic Oscillator | 72.24 | 72.40 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.